- Conditions
- Healthy
- Interventions
- AC 170 0.24%
- Drug
- Lead sponsor
- Aciex Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Allergic Conjunctivitis
- Interventions
- AC-170 0.24%, AC-170 0%
- Drug
- Lead sponsor
- Aciex Therapeutics, Inc.
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Allergic Conjunctivitis
- Interventions
- AC-170 0.24%, AC-170 0%
- Drug
- Lead sponsor
- Aciex Therapeutics, Inc.
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Healthy Subjects
- Interventions
- AC-170 0.24%, AC-170 Vehicle
- Drug
- Lead sponsor
- Nicox Ophthalmics, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Normal Ocular Health
- Interventions
- AC-170 0.17%, AC-170 0.24% (Formulation 1), AC-170 0.24% (Formulation 2), Olopatadine hydrochloride 0.2%/Tears Naturale II
- Drug
- Lead sponsor
- Aciex Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Allergic Conjunctivitis
- Interventions
- AC-170 0.05%, AC-170 0.1%, AC-170 0.24%, AC-170 0%
- Drug
- Lead sponsor
- Aciex Therapeutics, Inc.
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Allergic Conjunctivitis
- Interventions
- AC-170 0.24%, AC-170 0%
- Drug
- Lead sponsor
- Aciex Therapeutics, Inc.
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Atopic Disease (Including Allergic Conjunctivitis)
- Interventions
- Drug: AC-170 0.24%, AC-170 0%
- Drug
- Lead sponsor
- Aciex Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts